TY - JOUR
T1 - Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats
AU - Jiménez Pérez, Julio César
AU - Casillas Ramírez, Araní
AU - Torres González, Liliana
AU - Muñoz Espinosa, Linda Elsa
AU - Perales Quintana, Marlene Marisol
AU - Alarcón Galván, Gabriela
AU - Zapata Chavira, Homero
AU - Guzmán De La Garza, Francisco Javier
AU - Cámara Lemarroy, Carlos Rodrigo
AU - Fernández Garza, Nancy Esthela
AU - Pérez Rodríguez, Edelmiro
AU - Cordero Pérez, Paula
N1 - Publisher Copyright:
© 2016 Julio César Jiménez Pérez et al.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Introduction. Ischemia/reperfusion (IR) injury, often associated with liver surgery, is an unresolved problem in the clinical practice. Spironolactone is an antagonist of aldosterone that has shown benefits over IR injury in several tissues, but its effects in hepatic IR are unknown. Objective. To evaluate the effect of spironolactone on IR-induced damage in liver. Materials and Methods. Total hepatic ischemia was induced in rats for 20 min followed by 60 min of reperfusion. Spironolactone was administered and hepatic injury, cytokine production, and oxidative stress were assessed. Results. After IR, increased transaminases levels and widespread acute inflammatory infiltrate, disorganization of hepatic hemorrhage trabeculae, and presence of apoptotic bodies were observed. Administration of SPI reduced biochemical and histological parameters of liver injury. SPI treatment increased IL-6 levels when compared with IR group but did not modify either IL-1β or TNF-α with respect to IR group. Regarding oxidative stress, increased levels of catalase activity were recorded in IR + SPI group in comparison with group without treatment, whereas MDA levels were similar in IR + SPI and IR groups. Conclusions. Spironolactone reduced the liver damage induced by IR, and this was associated with an increase in IL-6 production and catalase activity.
AB - Introduction. Ischemia/reperfusion (IR) injury, often associated with liver surgery, is an unresolved problem in the clinical practice. Spironolactone is an antagonist of aldosterone that has shown benefits over IR injury in several tissues, but its effects in hepatic IR are unknown. Objective. To evaluate the effect of spironolactone on IR-induced damage in liver. Materials and Methods. Total hepatic ischemia was induced in rats for 20 min followed by 60 min of reperfusion. Spironolactone was administered and hepatic injury, cytokine production, and oxidative stress were assessed. Results. After IR, increased transaminases levels and widespread acute inflammatory infiltrate, disorganization of hepatic hemorrhage trabeculae, and presence of apoptotic bodies were observed. Administration of SPI reduced biochemical and histological parameters of liver injury. SPI treatment increased IL-6 levels when compared with IR group but did not modify either IL-1β or TNF-α with respect to IR group. Regarding oxidative stress, increased levels of catalase activity were recorded in IR + SPI group in comparison with group without treatment, whereas MDA levels were similar in IR + SPI and IR groups. Conclusions. Spironolactone reduced the liver damage induced by IR, and this was associated with an increase in IL-6 production and catalase activity.
UR - http://www.scopus.com/inward/record.url?scp=84954286581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954286581&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/02d970fa-8b4b-35e7-9fb1-223764aeaf4a/
U2 - 10.1155/2016/3196431
DO - 10.1155/2016/3196431
M3 - Article
C2 - 26798418
SN - 1942-0900
VL - 2016
SP - 3196431
JO - Oxidative Medicine and Cellular Longevity
JF - Oxidative Medicine and Cellular Longevity
M1 - 3196431
ER -